Contact this trialFirst, we need to learn more about you.
Histone Deacetylase Inhibitor
Vorinostat + Ustekinumab for Crohn's Disease
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the safety of using the drug vorinostat to treat Crohn's disease, a chronic inflammatory bowel disease. Vorinostat may help to reduce the inflammation process of CD and relieve symptoms. Participants who respond to Vorinostat will be invited to an extension phase of treatment with Vorinostat and possibly a maintenance treatment using Ustekinumab.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service